Kazia Therapeutics Limited KZIA

NAS: KZIA | ISIN: US48669G1058 30/04/2025

3,590 USD (+3,46%)

(+3,46%) 30/04/2025

Grafiek Kazia Therapeutics Limited

Grafiek Kazia Therapeutics Limited

1 dag1d 3,46%
1 week1w 5,05%
1 maand1m 350,68%
3 maanden3m 140,95%
6 maanden6m -34,96%
1 jaar1j 1.101,91%
5 jaar5j 31,99%

Kazia Therapeutics Limited in het nieuws

Toon enkel gratis nieuws

31 maart 2025 · Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil · Persbericht

12 september 2024 · Kazia Executes Licensing Agreement With Qimr Berghofer · Persbericht

10 juli 2024 · Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma · Persbericht

27 juni 2024 · Kazia Announces Upcoming Dipg Data Presentations At Ispno And Publication In European Journal Of Cancer · Persbericht

23 mei 2024 · Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement · Persbericht

1 mei 2024 · Kazia Reports Successful Stage 1 Completion Of The Evt801 Phase 1 Clinical Trial In Advanced Cancer Patients · Persbericht

21 maart 2024 · Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases · Persbericht

13 maart 2024 · Kazia announces presentation of new data at AACR Annual Meeting · Persbericht

21 februari 2024 · Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint · Persbericht

18 januari 2024 · Kazia Continues Board Renewal With Two New Appointments · Persbericht

Profiel Kazia Therapeutics Limited

Gezondheidstechnologie

Medicinale en botanische productie

Werknemers: 60

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe